Loading clinical trials...
Loading clinical trials...
Discover 21,047 clinical trials near Pittsburgh, Pennsylvania. Find research studies in your area.
Showing 15061-15080 of 21,047 trials
NCT03372031
Does active piano practice help recover hand dexterity in older adults, or does social interaction and music-listening alone affect motor performance? Researchers hypothesized improved dexterity after active piano playing, but not after passive piano listening. 15 residents of a retirement community were partnered together and completed 2 two-week piano training modules. In module 1, one partner played piano exercises and songs while the other listened. In module 2, partners switched roles. The Purdue Pegboard Test and Box and Block Test assessed fine and gross motor dexterity, before, between, and after the training modules. A repeated measures ANOVA showed a main effect of time on overall fine and gross motor function, but there was no main effect of playing versus listening. Results did not support the hypothesis, but indicate that piano-based therapy requires greater than 2 weeks to begin improving dexterity and may influenced co-occurring socialization.
NCT02252146
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B Cell Lymphoma (DLBCL). MYD88 is an initial adapter linker protein in the signaling pathway of the Toll Like Receptors (TLRs), including the endosomal TLRs 7, 8, and 9, for which the ligands are nucleic acids. IMO-8400 is an oligonucleotide specifically designed to inhibit ligand activation of TLRs 7,8, and 9. Recent studies indicate that in the presence of L265P mutation ligand activation of those TLRs results in markedly increased signaling with subsequent increased cell activation, cell survival, and cell proliferation. The scientific rationale for assessing the use of IMO-8400 to treat patients with DLBCL and the L265P mutation is based on laboratory observations that IMO-8400 inhibits ligand-based activation of cells with the mutation and decreases the survival and proliferation of the cell populations responsible for the propagation of the disease.